BDTX Black Diamond Therapeutics Inc
Price (delayed)
$5.66
Market cap
$319.82M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.5
Enterprise value
$306.71M
Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of small molecule, tumor-agnostic therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers. Black Diamond
Highlights
The company's equity rose by 35% YoY and by 6% QoQ
Black Diamond Therapeutics's EPS has increased by 34% YoY and by 10% QoQ
The quick ratio has grown by 2.8% YoY but it has contracted by 2.5% from the previous quarter
Key stats
What are the main financial stats of BDTX
Market
Valuations
Earnings
Shares outstanding
56.5M
Market cap
$319.82M
Enterprise value
$306.71M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.87
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$80.55M
EBITDA
-$80.18M
Free cash flow
-$68.24M
Per share
Balance sheet
Liquidity
EPS
-$1.5
Free cash flow per share
-$1.24
Book value per share
$1.97
Revenue per share
$0
TBVPS
$2.72
Total assets
$149.99M
Total liabilities
$38.97M
Debt
$20.53M
Equity
$111.02M
Working capital
$108.32M
Debt to equity
0.18
Current ratio
6.87
Quick ratio
6.71
Net debt/EBITDA
0.16
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-51.7%
Return on equity
-69.1%
Return on invested capital
-69.3%
Return on capital employed
-61.2%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BDTX stock price
How has the Black Diamond Therapeutics stock price performed over time
Intraday
4.81%
1 week
-7.21%
1 month
21.98%
1 year
62.18%
YTD
101.42%
QTD
21.46%
Financial performance
How have Black Diamond Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$87.24M
Net income
-$80.55M
Gross margin
N/A
Net margin
N/A
The net income has grown by 2.7% YoY
BDTX's operating income is down by 2.5% QoQ
Growth
What is Black Diamond Therapeutics's growth rate over time
Valuation
What is Black Diamond Therapeutics stock price valuation
P/E
N/A
P/B
2.87
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Black Diamond Therapeutics's EPS has increased by 34% YoY and by 10% QoQ
The P/B is 59% higher than the last 4 quarters average of 1.8 and 51% higher than the 5-year quarterly average of 1.9
The company's equity rose by 35% YoY and by 6% QoQ
Efficiency
How efficient is Black Diamond Therapeutics business performance
Black Diamond Therapeutics's ROE has increased by 10% YoY and by 5% from the previous quarter
The ROA rose by 8% YoY and by 3.9% QoQ
BDTX's return on invested capital is up by 6% since the previous quarter and by 4.8% year-on-year
Dividends
What is BDTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BDTX.
Financial health
How did Black Diamond Therapeutics financials performed over time
Black Diamond Therapeutics's total assets has increased by 25% YoY and by 5% from the previous quarter
BDTX's current ratio is up by 2.7% year-on-year but it is down by 2.6% since the previous quarter
The debt is 82% smaller than the equity
Black Diamond Therapeutics's debt to equity has decreased by 38% YoY and by 10% QoQ
The company's equity rose by 35% YoY and by 6% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.